Similar articles

• Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients.

  van Megen HJ, Westenberg HG, den Boer JA. van Megen HJ, et al. Biol Psychiatry. 1996 Oct 15;40(8):804-6. doi: 10.1016/0006-3223(96)00250-8. Biol Psychiatry. 1996. PMID: 8894076 Clinical Trial. No abstract available.
• Tiagabine improves panic and agoraphobia in panic disorder patients.

  Zwanzger P, Baghai TC, Schüle C, Minov C, Padberg F, Möller HJ, Rupprecht R. Zwanzger P, et al. J Clin Psychiatry. 2001 Aug;62(8):656-7. doi: 10.4088/jcp.v62n0813d. J Clin Psychiatry. 2001. PMID: 11561942 No abstract available.
• The use of the reversible monoamine oxidase-A inhibitor brofaromine in social phobia complicated by panic disorder with or without agoraphobia.

  Bakish D. Bakish D. J Clin Psychopharmacol. 1994 Feb;14(1):74-5. doi: 10.1097/00004714-199402000-00011. J Clin Psychopharmacol. 1994. PMID: 8151007 Clinical Trial. No abstract available.
• Serotonin, panic disorder and agoraphobia: short-term and long-term efficacy of citalopram in panic disorders.

  Humble M, Wistedt B. Humble M, et al. Int Clin Psychopharmacol. 1992 Jun;6 Suppl 5:21-39. Int Clin Psychopharmacol. 1992. PMID: 1431019 Review.
• [Panic disorder and agoraphobia: what is effective?].

  Bandelow B, Sievert K, Röthemeyer M, Hajak G, Broocks A, Rüther E. Bandelow B, et al. Fortschr Neurol Psychiatr. 1995 Nov;63(11):451-64. doi: 10.1055/s-2007-996646. Fortschr Neurol Psychiatr. 1995. PMID: 8575719 Review. German.